retatrutide developer eli lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application retatrutide developer eli lilly Retatrutide,

For UK availability, visit the Retatrutide UK page

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome

Some people feel stuck doing all the right things and still not seeing changes

Curr Opin Endocrinol Diabetes Obes (2013) 20(2):8797

Experimental investigations have demonstrated that cholangiocytes are sensitive to GLP-1 and respond with augmented proliferation, potentially increasing the risk of duct obstruction [47,48]

doi: 10.1007/s10620-025-08964-6 104 AndersonSRAyoubMCoatsSMcHenrySTanTDeepakP